Peer-influenced content. Sources you trust. No registration required. This is HCN.

Results of KEYNOTE-716 Trial May ‘Level the Playing Field Against Melanoma’

The results, presented during the virtual ESMO Congress 2021, will substantially change the population of patients with melanoma who undergo treatment in the adjuvant setting, according to Jason J. Luke, MD: “Patients with stage IIB/C melanoma have similar rates of recurrence and melanoma specific survival to those with stage IIIA/B disease. Despite this, adjuvant anti-PD-1 immunotherapy has only been available in standard practice for stage III disease. The results of KEYNOTE-716 will facilitate access to anti-PD-1 for stage IIB/C patients and, in a sense, level the playing field against melanoma.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form